Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Gets Downgrade from Wall Street Zen

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other equities analysts have also issued reports about the company. TD Cowen boosted their price target on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Royal Bank Of Canada lifted their price objective on shares of Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Monday, November 2nd. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. Finally, Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.33.

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $16.46 on Friday. The firm has a market cap of $2.21 billion, a PE ratio of 7.19 and a beta of 1.40. The company has a current ratio of 6.12, a quick ratio of 5.67 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $16.48 and a 200-day moving average price of $15.68. Aurinia Pharmaceuticals has a 1-year low of $13.52 and a 1-year high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Friday, October 30th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.22 by $0.01. Aurinia Pharmaceuticals had a return on equity of 22.99% and a net margin of 97.68%. The company had revenue of $83.70 million for the quarter, compared to analyst estimates of $83.61 million. As a group, equities research analysts expect that Aurinia Pharmaceuticals will post 0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Signaturefd LLC boosted its holdings in Aurinia Pharmaceuticals by 360.0% during the 3rd quarter. Signaturefd LLC now owns 1,794 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,404 shares during the last quarter. Nykredit A S purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $35,000. Global Retirement Partners LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $41,000. Quantbot Technologies LP purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $45,000. Finally, Frazier Financial Advisors LLC lifted its position in shares of Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 2,793 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.